Market Intelligence, Clinical Progress, and High-Purity Reagents for Vascular and Oncological Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SEMA3G drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SEMA3G Recombinant Protein (Fc Tag) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed (Native Glycosylation). Perfect for ligand-receptor binding assays. |
View SEMA3G Products |
| Gene Delivery | SEMA3G Promise-ORF / Lentivirus Full-length ORF for stable cell line construction to preserve native conformation. |
View SEMA3G Products |
| Benchmark Ab | Anti-SEMA3G Recombinant Antibody Recombinant positive control derived from benchmark research sequences. |
View SEMA3G Products |
| Validator | SEMA3G siRNA Set Target-specific knockdown verification in endothelial and tumor cell lines. |
View SEMA3G Products |
| Related Target A | NRP2 (Neuropilin-2) Primary functional co-receptor for SEMA3G; essential for validating ligand-receptor blocking. |
View NRP2 Products |
| Related Target B | PLXNA1 (Plexin A1) Signal transducing coreceptor partnering with NRP2 in the SEMA3G signaling complex. |
View PLXNA1 Products |
| Related Target C | SEMA3A (Semaphorin 3A) Homologous family member required for selectivity and counter-screening assays. |
View SEMA3A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Homology Overlap (SEMA3A/3F cross-reactivity) | Homolog panel proteins (SEMA3A, SEMA3F) strictly verified by mass spectrometry to ensure accurate selectivity screening |
| Dimerization & Glycosylation Requirements | HEK293 mammalian expression system guarantees correct disulfide-linked homodimerization and native post-translational modifications |
| Lack of Validated Control Reagents | Sequence-verified clinical-grade benchmark antibodies included to establish reliable assay baselines |
| Non-Specific Binding in Assay Formats | High-purity (>95% by SDS-PAGE) and endotoxin-controlled (<1.0 EU/μg) formulations minimize background noise |
Live SEMA3G R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SEMA3G therapeutics is intensifying, with major players shifting focus from traditional mAbs to recombinant protein therapies and targeted antibody-based modulators. As first-generation therapies reach the clinic, the next wave of R&D is targeting vascular remodeling in diabetic retinopathy and microenvironmental modulation in solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Recombinant Protein (Agonist) | Academic Medical Centers, Biotech Startups | Diabetic Retinopathy, Diabetic Macular Edema | Endothelial Barrier Assays (Requires high-purity SEMA3G-Fc homodimers) |
| Monoclonal Antibody (Antagonist) | Oncology-focused Biopharma | Glioblastoma, Solid Tumors | Receptor Blocking Assays (Requires SEMA3G-NRP2 interaction screening) |
| Gene Therapy / mRNA | In Vivo Delivery Specialists | Ischemic Retinopathies | Expression Validation (Requires sequence-verified SEMA3G lentivirus & qPCR primers) |